Noguchi-Shinohara Moeko, Sakashita Yasuhiro, Nakano Hiroto, Muramatsu Daiki, Hikishima Sadao, Komatsu Junji, Murakami Hidetomo, Mori Yukiko, Ono Kenjiro
Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Department of Neurology, School of Medicine, Showa University, Tokyo, Japan.
J Prev Alzheimers Dis. 2025 Jan;12(1):100003. doi: 10.1016/j.tjpad.2024.100003. Epub 2025 Jan 1.
Plasma amyloid-β (Aβ) markers are significant predictors of Aβ pathology. However, their prognostic value for cognition in patients with Alzheimer's disease (AD) is unknown. We compared plasma amyloid-β precursor protein (APP) and Aβ levels between cognitively unimpaired participants (CU) and those with MCI due to AD and AD dementia. The CU group was divided into CU+ or CU- groups according to presence of Aβ pathology. All patients with AD exhibited Aβ pathology. The plasma APP/Aβ ratio was significantly elevated in patients with CU+, MCI+, and AD+ compared with those with CU-. Furthermore, the plasma APP/Aβ ratio was significantly correlated with the MMSE score (rs = -0.544, p < 0.001). Analysis of the Aβ+ group revealed that the significant relationship between MMSE score and plasma APP/Aβ ratio remained unchanged (rs = -0.244, p = 0.027). Therefore, we conclude that the plasma APP/Aβ ratio is associated with cognition in patients with AD.
血浆淀粉样蛋白-β（Aβ）标志物是Aβ病理状态的重要预测指标。然而，它们对阿尔茨海默病（AD）患者认知功能的预后价值尚不清楚。我们比较了认知未受损参与者（CU）与因AD和AD痴呆导致的轻度认知障碍（MCI）患者之间的血浆淀粉样蛋白-β前体蛋白（APP）和Aβ水平。CU组根据Aβ病理状态分为CU+或CU-组。所有AD患者均表现出Aβ病理状态。与CU-组相比，CU+、MCI+和AD+组患者的血浆APP/Aβ比值显著升高。此外，血浆APP/Aβ比值与MMSE评分显著相关（rs = -0.544，p < 0.001）。对Aβ+组的分析显示，MMSE评分与血浆APP/Aβ比值之间的显著关系保持不变（rs = -0.244，p = 0.027）。因此，我们得出结论，血浆APP/Aβ比值与AD患者的认知功能相关。
